Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Boehringer Ingelheim
Mallinckrodt
Daiichi Sankyo
Cantor Fitzgerald
Harvard Business School

Generated: August 22, 2019

DrugPatentWatch Database Preview

Abatacept - Biologic Drug Details

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for abatacept
Tradenames:1
Patents:65
Applicants:1
BLAs:1
Suppliers: see list1
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for abatacept
Pharmacology for abatacept
Ingredient-typeRecombinant Fusion Proteins
Physiological EffectDecreased Cytokine Activity

US Patents for abatacept

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bristol Myers Squibb ORENCIA abatacept INJECTABLE; IV (INFUSION) 125118 001 2005-12-23 ➤ Sign Up SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) 2033-03-11 RX search
Bristol Myers Squibb ORENCIA abatacept INJECTABLE; IV (INFUSION) 125118 001 2005-12-23 ➤ Sign Up Momenta Pharmaceuticals, Inc. (Cambridge, MA) 2029-01-22 RX search
Bristol Myers Squibb ORENCIA abatacept INJECTABLE; IV (INFUSION) 125118 001 2005-12-23 ➤ Sign Up University of Miami (Miami, FL) 2030-10-19 RX search
Bristol Myers Squibb ORENCIA abatacept INJECTABLE; IV (INFUSION) 125118 001 2005-12-23 ➤ Sign Up OXFORD UNIVERSITY INNOVATION LIMITED (Oxford, GB) 2034-01-13 RX search
Bristol Myers Squibb ORENCIA abatacept INJECTABLE; IV (INFUSION) 125118 001 2005-12-23 ➤ Sign Up CureVac AG (Tubingen, DE) 2032-02-15 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for abatacept

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2008014,C1372696 Lithuania ➤ Sign Up PRODUCT NAME: ABATACEPTUM; REGISTRATION NO/DATE: EU/1/07/389/001, 2007-05-21, EU/1/07/389/002, 2007-05-21, EU/1/07/389/003 20070521
0844 Netherlands ➤ Sign Up PRODUCT NAME: IBRUTINIB, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/14/945 - C(2016)3293 20160530
0911 Netherlands ➤ Sign Up PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: EU/1/17/1196 20170627
90021-0 Sweden ➤ Sign Up PRODUCT NAME: IBRUTINIB ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/14/945 20141023
2015 00021 Denmark ➤ Sign Up PRODUCT NAME: IBRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 20141023
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Merck
Moodys
Fish and Richardson
McKinsey
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.